Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Leviker is a consumer health supplement developed by Stragen Pharma Group, designed to support liver function and metabolic health. It is primarily indicated for individuals with non-alcoholic fatty liver disease (NAFLD) or metabolic-associated fatty liver disease (MAFLD). The formulation consists of a standardized extract of *Prunus mume* (Japanese apricot), which contains bioactive triterpenoids such as oleanolic acid and ursolic acid, alongside choline bitartrate. These components work to reduce oxidative stress and inflammation in the liver while supporting normal lipid metabolism and preventing hepatic fat accumulation. Leviker is marketed as a natural approach to maintaining healthy liver enzyme levels (ALT and AST) and overall hepatic wellness.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Leviker.